China Market Intelligence: Reading a Market Before It Moves

Year

2025

Company

Blistex

Project Type

Market Intelligence

Why it matters

In the U.S., you open Nielsen and the picture is mostly there. In China, syndicated data exists but coverage is fragmented and unreliable on its own. Sales data lives in Moojing across three e-commerce platforms. Regulatory filings live in NMPA. Social listening is scattered across Douyin, Xiaohongshu, and Weibo - none of which talk to each other. Competitive intelligence means reading patent filings, government certification reports, and distributor marketing materials, most of which only exist in Mandarin. You don't get a picture - you build one.

At most companies, that's the job of a research agency or an in-market insights team. At Blistex, it was me - sourcing the data, cleaning it, connecting it across platforms, and turning it into something leadership could actually use to make portfolio and pricing decisions. The result was a 38-slide evidence pack that became the analytical foundation for the company's China strategy.

Why it matters

What I built

The raw data was noisy. Hundreds of brands, dozens of ingredient trends, three major e-commerce platforms, two social platforms, and no pre-built framework connecting any of it. The hard part wasn't access - it was judgment. Knowing which signals matter, which are noise, and how to structure the output so a VP who's never operated in China can make a confident decision in a 30-minute meeting.

I built three frameworks that did that:

First: a market bifurcation map that sorted the entire lip care category into two strategic lanes - "Science" (clinical proof, ingredient stories) vs. "Sensory" (flavors, lifestyle). The data made the growth story undeniable - one chart ended a months-long internal debate about brand positioning.
Second: a price tier segmentation that showed exactly where growth was concentrated and where Blistex was stuck.
Third: an ingredient lifecycle model using skincare trend data as a 12–24 month leading indicator for lip care - giving the NPD team a forward view they'd never had.

Each framework was designed to collapse complexity into a decision. Not a report to read - a tool to use.

The unlock

The top competitor hadn't just marketed better - they'd built an institutional moat with proprietary biotech, government-backed clinical tests, and category standard-setting authority. Competing on their terms would require R&D investment Blistex didn't have in-market. But Blistex had something they didn't: a global footprint and Western medical credibility. The framework I built reframed the strategy from "catch up in China" to "leverage globally and deploy locally" - one clinical investment usable across 12+ markets.

What changed

The evidence pack directly shaped portfolio architecture, NPD ingredient decisions backed by lifecycle data instead of intuition, a repositioned Joint Business Plan with the China distributor, and the creative brief for a newly onboarded social media agency.

I also negotiated the market intelligence platform contract and stood up a quarterly reporting cadence - so the analysis didn't die as a one-time deck but became an operating system.